Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Research Article

Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database

Author(s): Reddy Neha, Elsa Beulah, Bellapu Anusha, Sharma Vasista, Chacko Stephy and Viswam Subeesh*

Volume 16, Issue 2, 2021

Published on: 28 June, 2020

Page: [168 - 173] Pages: 6

DOI: 10.2174/1574884715666200628113508

Price: $65

Abstract

Background: Signal strength for any drug-event combination can be determined using disproportionality analysis. Vemurafenib is a BRAF inhibitor approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of metastatic melanoma. This study aims to identify the signal strength of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) associated with vemurafenib using disproportionality analysis in FDA database of Adverse Event Reporting System (FAERS).

Methods: Data were obtained from the public release of data in FAERS. The case/non-case method was adopted for the analysis of the association between vemurafenib use and DRESS. The data mining algorithm used for the analysis was the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR). A value of ROR-1.96SE>1, PRR≥2 was considered as positive signal strength.

Results: A total of 7,171 reports for DRESS have been reported in the FDA database. Amongst which, 125 reports were associated with vemurafenib. A cumulative ROR of 17.72 (95% CI 14.83; 21.18) and PRR of 17.46 (95% CI 14.65; 20.81) were observed. Combination treatment of vemurafenib with cobimetinib had a higher number of reports (100) with ROR of 103.42 (84.13- 127.14) and PRR of 94.52 (78.26- 114.15). Four deaths were reported and the non-death serious reports included hospitalization, life-threatening, disability, and other serious events with 61, 11, 2 and 39 reports, respectively.

Conclusion: Positive signal strength was observed for vemurafenib associated DRESS. The signal strength was higher for vemurafenib in combination with cobimetinib than vemurafenib alone. Health care professionals should be cautious about encountering serious adverse events and should report such events to the regulatory authorities.

Keywords: Vemurafenib, DRESS, Disproportionality analysis, FAERS, vemurafenib, lymphadenopathy.

Graphical Abstract
[1]
Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf 2015; 14(4): 559-70.
[http://dx.doi.org/10.1517/14740338.2015.1011618] [PMID: 25648338]
[2]
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
[http://dx.doi.org/10.1038/nature00766] [PMID: 12068308]
[3]
Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29(10): 1239-46.
[http://dx.doi.org/10.1200/JCO.2010.32.4327] [PMID: 21343559]
[4]
Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149(5): 1018-22.
[http://dx.doi.org/10.1111/j.1365-2133.2003.05584.x] [PMID: 14632808]
[5]
Isaacs M, Cardones AR, Rahnama-Moghadam S. DRESS syndrome: Clinical myths and pearls. Cutis 2018; 102(5): 322-6.
[PMID: 30566546]
[6]
Ichiche M, Kiesch N, De Bels D. DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med 2003; 14(8): 498-500.
[http://dx.doi.org/10.1016/j.ejim.2003.09.004] [PMID: 14962704]
[7]
Munch M, Peuvrel L, Brocard A, et al. Early-onset vemurafenib-Induced DRESS syndrome. Dermatology (Basel) 2016; 232(1): 126-8.
[http://dx.doi.org/10.1159/000439272] [PMID: 26418832]
[8]
Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS. Vemurafenib-induced DRESS. JAMA Dermatol 2013; 149(10): 1242-3.
[http://dx.doi.org/10.1001/jamadermatol.2013.5278] [PMID: 23986488]
[9]
Gey A, Milpied B, Dutriaux C, et al. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? J Eur Acad Dermatol Venereol 2016; 30(1): 178-9.
[http://dx.doi.org/10.1111/jdv.12685] [PMID: 25175726]
[10]
Pinard C, Mignard C, Samain A, Duval-Modeste A-B, Joly P. Successful use of dabrafenib after the occurrence of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) induced by vemurafenib. JAAD Case Rep 2017; 3(6): 532-3.
[http://dx.doi.org/10.1016/j.jdcr.2017.06.027] [PMID: 29296640]
[11]
Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data mining applications in engineering and medicine: InTech 2012.
[12]
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809-19.
[http://dx.doi.org/10.1056/NEJMoa1002011] [PMID: 20818844]
[13]
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366(8): 707-14.
[http://dx.doi.org/10.1056/NEJMoa1112302] [PMID: 22356324]
[14]
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15(3): 323-32.
[http://dx.doi.org/10.1016/S1470-2045(14)70012-9] [PMID: 24508103]
[15]
Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients. Ann Oncol 2013; 24(6): 1691-7.
[http://dx.doi.org/10.1093/annonc/mdt015] [PMID: 23406731]
[16]
Shiohara T, Inaoka M, Kano Y. Drug-Induced Hypersensitivity Syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006; 55(1): 1-8.
[http://dx.doi.org/10.2332/allergolint.55.1] [PMID: 17075280]
[17]
Picard D, Janela B, Descamps V, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A multiorgan antiviral T cell response. Science translational medicine 2010; 2(46): 46ra62-2.
[18]
Brégeon B, Bernier C, Josselin N, et al. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases. J Am Acad Dermatol 2019; 80(2): 558-62.
[http://dx.doi.org/10.1016/j.jaad.2018.07.029] [PMID: 30081108]
[19]
Funck-Brentano E, Duong T-A, Bouvresse S, et al. Therapeutic management of DRESS: A retrospective study of 38 cases. J Am Acad Dermatol 2015; 72(2): 246-52.
[http://dx.doi.org/10.1016/j.jaad.2014.10.032] [PMID: 25592341]
[20]
Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 2014; 37(4): 283-94.
[http://dx.doi.org/10.1007/s40264-014-0150-2] [PMID: 24643967]
[21]
Beulah E, Reddy N, Subeesh V, Maheswari E, Pudi C. Weber effect: An extended analysis for ten years of reporting trends in FDA Adverse Event Reporting System (FAERS). Value Health 2018; 21: S369.
[http://dx.doi.org/10.1016/j.jval.2018.09.2200]
[22]
Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig 2017; 37(5): 415-22.
[http://dx.doi.org/10.1007/s40261-017-0503-6] [PMID: 28224371]
[23]
Neha R, Beulah E, Anusha B, Vasista S, Stephy C, Subeesh V. Aromatase inhibitors associated osteonecrosis of jaw: Signal refining to identify pseudo safety signals. Int J Clin Pharm 2020; 42(2): 721-7.
[http://dx.doi.org/10.1007/s11096-020-01018-z] [PMID: 32270377]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy